Viridian Therapeutics Inc

VRDN

Company Profile

  • Business description

    Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

  • Contact

    221 Crescent Street
    Suite 103A
    WalthamMA02453
    USA

    T: +1 617 272-4600

    E: [email protected]

    https://www.viridiantherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    143

Stocks News & Analysis

stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.
stocks

Morningstar analyst reacts to Macquarie Group’s earnings

Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks

Undervalued ASX share showing progress in global efforts

More clarity on the path forward in the UK.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,966.703.200.04%
CAC 407,882.1481.261.04%
DAX 4024,200.18229.820.96%
Dow JONES (US)44,837.5664.36-0.14%
FTSE 1009,104.5523.110.25%
HKSE25,524.4537.68-0.15%
NASDAQ21,178.5870.270.33%
Nikkei 22540,674.55323.72-0.79%
NZX 50 Index12,936.4125.670.20%
S&P 5006,389.771.130.02%
S&P/ASX 2008,704.606.900.08%
SSE Composite Index3,609.7111.770.33%

Market Movers